Literature DB >> 11956387

Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: a pilot study.

Mauricio Lynn1, Igor Jerokhimov, Dory Jewelewicz, Charles Popkin, Edward W Johnson, Qammar N Rashid, Margareth Brown, Uri Martinowitz, Stephen M Cohn.   

Abstract

BACKGROUND: Recombinant factor VIIa (rFVIIa) is used for treatment of bleeding episodes in hemophilia patients who develop inhibitors to factors VIII and IX. We tested the hypothesis that administration of rFVIIa early after injury would decrease bleeding and improve survival after experimental hepatic trauma.
METHODS: Anesthetized swine were cannulated for blood sampling and hemodynamic monitoring. Avulsion of left median lobe of the liver induced uncontrolled hemorrhage. After a 10% reduction of mean arterial pressure, animals were blindly randomized to receive intravenous rFVIIa (180 microg/kg) (n = 6) or placebo (n = 7).
RESULTS: Mortality was 43% (three of seven) in controls versus 0% with rFVIIa (p = 0.08, chi2). Significantly shorter prothrombin time and higher mean arterial pressures were observed in the rFVIIa group.
CONCLUSION: Intravenous administration of rFVIIa early after induction of hemorrhage shortens prothrombin time and improves mean arterial pressure. A trend toward improved survival was observed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11956387     DOI: 10.1097/00005373-200204000-00016

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  5 in total

1.  The influence of coagulation and inflammation research on the improvement of polytrauma care.

Authors:  M Perl; M Huber-Lang; F Gebhard
Journal:  Eur J Trauma Emerg Surg       Date:  2011-11-09       Impact factor: 3.693

Review 2.  [Treatment of hemorrhagic shock. New therapy options].

Authors:  W G Voelckel; A von Goedecke; D Fries; A C Krismer; V Wenzel; K H Lindner
Journal:  Anaesthesist       Date:  2004-12       Impact factor: 1.041

3.  Prothrombin complex concentrate mitigates diffuse bleeding after cardiopulmonary bypass in a porcine model.

Authors:  F Kaspereit; S Hoffmann; I Pragst; G Dickneite
Journal:  Br J Anaesth       Date:  2010-08-17       Impact factor: 9.166

4.  Causes of death in U.S. Special Operations Forces in the global war on terrorism: 2001-2004.

Authors:  John B Holcomb; Neil R McMullin; Lisa Pearse; Jim Caruso; Charles E Wade; Lynne Oetjen-Gerdes; Howard R Champion; Mimi Lawnick; Warner Farr; Sam Rodriguez; Frank K Butler
Journal:  Ann Surg       Date:  2007-06       Impact factor: 12.969

Review 5.  Preclinical trauma studies of recombinant factor VIIa.

Authors:  Martin A Schreiber; John B Holcomb; Rasmus Rojkjaer
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.